drugset / Trial / NCT00848055
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
Non-randomizedOpen-labelTreatment
Summary
The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chronic plaque psoriasis
Timeline
- Start
- 2008-12
- Primary completion
- 2010-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neihulizumab | Monoclonal antibody | 1 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 5 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 25 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 125 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 625 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 10 mg/kg | Intravenous |